8-K Announcements
6Material company update
Mar 4, 2025·SEC
Material company update
Feb 28, 2025·SEC
Material company update
Jan 8, 2025·SEC
Syros Pharmaceuticals faces a precarious financial outlook characterized by a complete cessation of revenue over the last three quarters and a rapid erosion of shareholder equity to negative $11.1 million as of 2024Q3. The company's heavy reliance on milestone...
Price trend, volume and key moving averages
Trailing total returns as of 9/26/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Benchmark SYRS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Syros Pharmaceuticals, Inc. (SYRS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.00 | $10.73K | -0.00 | -33.23% | -1656.34% | -227.95% | — | |
| $111.95 | $9.21B | -30.34 | -16.72% | -285.41% | -21.5% | — | |
| $7.59 | $489.72M | -5.93 | -0.3% | 2.94% | 1.91% | — | |
| $33.30 | $6.87B | -12.02 | — | -7585.86% | -69.59% | — | |
| $24.92 | $4.06B | -28.64 | 48.29% | -229.92% | -25.74% | — | |
| $280.78 | $7.83B | -20.83 | -100% | — | -34.15% | — |
Syros Pharmaceuticals, Inc. (SYRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Syros Pharmaceuticals, Inc. (SYRS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Mar 4, 2025·SEC
Feb 28, 2025·SEC
Jan 8, 2025·SEC
Get notified when SYRS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Syros Pharmaceuticals, Inc. (SYRS) stock FAQ — growth, dividends, profitability & financials explained
Syros Pharmaceuticals, Inc. (SYRS) reported $0.4M in revenue for fiscal year 2023.
Syros Pharmaceuticals, Inc. (SYRS) saw revenue decline by 33.2% over the past year.
Syros Pharmaceuticals, Inc. (SYRS) reported a net loss of $97.8M for fiscal year 2023.
Syros Pharmaceuticals, Inc. (SYRS) has a return on equity (ROE) of -227.9%. Negative ROE indicates the company is unprofitable.
Syros Pharmaceuticals, Inc. (SYRS) had negative free cash flow of $100.1M in fiscal year 2023, likely due to heavy capital investments.